Brandt J, Sieper J, Braun J
Rheumaklinik Bad Bramstedt, Innere Medizin, Rheumatologie, Immunologie, Oskar-Alexander-Str. 26, 24576 Bad Bramstedt, Germany.
Z Rheumatol. 2004 Jun;63(3):203-10. doi: 10.1007/s00393-004-0630-3.
The Spondyloarthritides (SpA) comprise a group of inflammatory rheumatic diseases which mostly affect the spine and the larger peripheral joints. The most common entities in this group are ankylosing spondylitis (AS) and undifferentiated spondyloarthritis (uSpA). Treatments with disease-modifying or remission-inducing properties for patients with AS are so far not available. However, in the light of relevant individual and socioeconomic consequences this is an unmet medical need. Recently, etanercept in addition to infliximab has shown substantial efficacy which might even be disease controlling. For both TNFalpha blocking agents, large randomized placebo-controlled trials have proven their efficacy with an acceptable profile of adverse events. In open trials these drugs also work in patients with uSpA. There is some hope now that the TNFalpha blocking agents could stop the development of AS in patients starting with uSpA.
脊柱关节炎（SpA）是一组炎性风湿性疾病，主要影响脊柱和较大的外周关节。该组中最常见的类型是强直性脊柱炎（AS）和未分化脊柱关节炎（uSpA）。迄今为止，尚无针对AS患者具有改善病情或诱导缓解特性的治疗方法。然而，鉴于相关的个人和社会经济后果，这是一项未满足的医疗需求。最近，除英夫利昔单抗外，依那西普也显示出显著疗效，甚至可能控制疾病。对于这两种肿瘤坏死因子α阻滞剂，大型随机安慰剂对照试验已证明其疗效且不良事件可接受。在开放试验中，这些药物对uSpA患者也有效。现在有一些希望，即肿瘤坏死因子α阻滞剂可以阻止以uSpA起病的患者发展为AS。
